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HAQAbstract Aim of the work: To study peroxisome proliferator activated receptor gamma (PPARc)
expression levels in the peripheral monocytes from rheumatoid arthritis (RA) patients and to clarify
its relation with disease activity, functional disability and drug therapy.
Patients and methods: Thirty RA patients (Group 1) were divided into two subgroups: Group 1A:
patients with moderate to high disease activity (n= 15); Group 1B: patients in remission or with low
disease activity (n= 15). Thirty healthy volunteers were included as control group. Disease activity
score in 28 joints (DAS-28) and Health Assessment Questionnaire (HAQ) were assessed in patients.
PPARc gene expression levels were assessed by real-time PCR in peripheral blood monocytes.
Results: The mean fold increase in monocyte PPARc expression levels was significantly higher
(p< 0.001) in patients (6.87 ± 0.9) compared to control, being significantly higher (p< 0.001) in
patients with remission or low activity (Group 1B) (7.6 ± 0.63) than patients with active RA (Group
1A) (6.13 ± 0.52). In RA patients, monocyte PPARc expression levels showed significant negative
correlations with morning stiffness durations, total joint count, visual analog scale for pain, DAS-28
and HAQ (p> 0.001) and with swelling joint count, erythrocyte sedimentation rate and platelet count
(p< 0.05). A significant correlation was present with disease duration (p< 0.05) while there were no
statistically significant correlations with any of Larsen score, C-reactive protein, hemoglobin concen-
trations, white blood cell count, rheumatoid factor or anti-cyclic citrullinated peptide titers (p> 0.05).
Conclusions: Ourfindings support the role ofPPARc in the pathophysiologyofRAand suggest that
over-expression of PPARc protein may have anti-rheumatic effects.
Publishing services provided by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Rheumatoid arthritis (RA) is a chronic inflammatory autoim-
mune disease characterized by persistent synovitis, systemic
inflammation, production of autoantibodies, and bone destruc-
tion preferentially involving the peripheral joints [1]. Mono-
cytes/macrophages infiltrate into the joints and produce
various bioactive factors, including cytokines andmatrix metal-
loproteinases (MMPs) that cause persistent inflammation and
lead to joint destruction [2]. Triggering receptor expressed on
myeloid cells-1 (TREM-1) is a recently identified molecule
involved in monocytic activation and inflammatory response.
Serum levels of TREM-1 were elevated in Egyptian RA patients
and correlated significantlywith clinical and laboratorymarkers
of disease activity as well as functional disability [3]. In another
study on Egyptian RA patients, proteinase-activated receptor
expression in monocytes was consistent with a pathogenic role
in the disease and its utility as a marker for disease activity
was suggested [4]. It was even reported that RA may be associ-
ated with an increased risk of lympho- and myelo-proliferative
malignancy [5].
Peroxisome proliferator activated receptors (PPARs)
belong to a subfamily of the nuclear receptor superfamily of
ligand-inducible transcription factors. Three PPAR isotypes
encoded by separate genes have been identified, PPARa,
PPARb/d, and PPARc [6]. PPARs can be activated by dietary
fatty acids and their metabolites and act as lipid sensors that,
upon activation, are able to markedly redirect metabolism that
control the expression of gene networks involved in adipogen-
esis, lipid metabolism, inflammation, and the maintenance of
metabolic homeostasis [7]. The PPARc protein exists in two
isoforms that are expressed from the same gene [8]. It was orig-
inally described in differentiating adipocytes, the two PPARc
isoforms show a distinct expression pattern: PPARc1 is abun-
dantly expressed in the adipose tissue, large intestine, and
hematopoietic cells, and to a lower degree in the kidney, liver,
muscles, pancreas, and small intestine while PPARc2 is
restricted to white and brown adipose tissues under physiolog-
ical conditions [9]. PPARc is also expressed in various immune
system-related cell types, particularly in antigen-presenting
cells such as macrophages and dendritic cells [10]. In these
cells, PPARc does not only regulate genes related to lipid
metabolism, but also immunity and inflammation related
genes [11]. PPARc was shown to be highly expressed in mouse
thioglycolate-elicited macrophages and its natural and syn-
thetic ligands inhibited the expression of several molecules
involved in the inflammatory process like inducible nitric oxide
synthase (iNOS), MMP-9 and scavenger receptor A [12].
The receptor attracted attention as a possible therapeutic tar-
get in inflammatory diseases when similar effects were reported
for the PPARc activators in human monocyte-derived macro-
phages [13]. This study aimed to assess PPARc expression levels
in the peripheral monocytes from RA patients in comparison
with healthy volunteers, and to clarify its relation with disease
activity, functional disability and drug therapy.
2. Patients and methods
This study was carried out on 30 RA patients attending the
outpatient clinic and the inpatient Department of Rheumatol-
ogy, Rehabilitation and Physical Medicine of BenhaUniversity Hospitals. All of them met the American College
of Rheumatology/European League against Rheumatism
(ACR/EULAR) rheumatoid arthritis classification criteria
[14]. They were divided into two subgroups according to the
28-joint disease activity score (DAS-28) [15]; Group 1A
included 15 patients with moderate or high disease activity
(DAS-28 > 3.2) and Group 1B included 15 patients in remis-
sion or with low disease activity (DAS-28 6 3.2). Another 30
apparently healthy volunteers with comparable age, sex and
social levels were included as the control group (Group 2).
An informed written consent was taken from patients included
in the study and it was approved by the Ethics Committee of
Faculty of Medicine of Benha University. Patients and con-
trols were excluded if they were tobacco smokers [16] or had
hypertension, diabetes or hypercholesterolemia.
All patients were subjected to full history taking, thorough
clinical examination, laboratory investigation, assessment of
disease activity by DAS-28 [15] and assessment of functional
capacity and disability using Health assessment Questionnaire
(HAQ) [17]. Erythrocyte sedimentation rate (ESR) was
assessed by the Westergren method, C-reactive protein (CRP)
by latex agglutination slide test for qualitative and semi-
quantitative determination in non-diluted serum, rheumatoid
factor (RF) was assessed by latex fixation test and anti-
citrullinated peptide antibody (ACPA) detected by ELISA.
Lipid profile was performed on blood samples obtained from
the patients after overnight fasting including: Total cholesterol
(TC) and triglycerides (TG) measured in plasma by the colori-
metric method using commercial assays; high density lipopro-
tein (HDL) using the direct HDL method (BS-300 Chemistry
analyzer) and low density lipid lipoprotein (LDL).
2.1. Monocyte PPARc expression by real time PCR
2.1.1. Sampling
Five ml of antecubital venous blood was collected from
patients and controls and immediately put in a heparin
containing vacutainer tube. Each sample was mixed and imme-
diately used in monocyte separation.
2.1.2. Isolation of monocytes
The buffy coat containing human monocytes was isolated
from heparinized venous blood by standard techniques of His-
topaque (density = 1077 g/cm3) gradient centrifugation (400g,
20 min, room temperature) as described [16]. Five ml of blood
was mixed with 5 ml of hanks balanced salt solution. After
proper mixing, the diluted blood was gently overlaid on the
surface of 3 ml of Histopaque. Tubes were centrifuged at
2000 rpm for 20 min. The buffy coat was carefully removed
by a pasteur pipette and washed 3 times in hanks balanced salt
solution. The cells were re-suspended in hanks balanced salt
solution and immediately used in genomic RNA extraction.
2.1.3. Genomic RNA extraction
Total RNA was extracted from the buffy coat using
Mammalian Total RNA purification Kit (Thermo scientific),
according to the manufacturer’s instructions. The purity of
the extracted RNA was detected through measurement by
UV spectrophotometer. Readings were taken at wave lengths
260 and 280 nm. Readings at 260 nm were >0.15. The ratio
between the absorbance values at 260 and 280 nm gives an
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Nanodrop Spectrophotometer 2000c USA.2.1.4. cDNA synthesis
Purified RNA samples were immediately reverse transcribed to
cDNA using a high-capacity cDNA reverse transcription kit
(Intron Biotechnology) according to the manufacturer’s
instructions. cDNA was stored at 80.
2.1.5. Relative quantitation of PPARc mRNA by real time PCR
using SYBR green
In this study, the calibrator sample is healthy control. A single-
plex reaction is used, where a single primer pair is present in a
well. Real-time PCR was carried out in a volume of 25 lL per
well in a 96-well optical reaction plate using Super Real Pre
Mix Plus (SYBRGreen) TIANGENBiotech (Beijing). Accord-
ing to the manufacturer’s instruction, each reaction contains
12.5 ll of 2  Super Real PreMix Plus, 0.75 ll of forward pri-
mer (10 lM), 0.75 ll of reverse primer (10 lM), 2.5 ll of
50  ROX Reference Dye, and 4 ll of cDNA template then
completed up to 25 ll with RNase-free ddH2O. The plate was
run on the ABI 7900HT (Applied Biosystems, USA). The
cycling conditions include initial denaturation at 95 C for
15 min followed by 40 repeated cycles of denaturation at
95 C for 10 s, annealing at 60 C for 20 s, followed by extension
at 72 C for 30 s. Primer sequence of PPARc was 50-CTATG
GAGTTCATGCTTGTG-30 (Forward) and 50-GTAC TGAG-
TACTGACA TTTATTT- 30 (Reverse) [18]. Primer sequence of
glyceraldehyde phosphate dehydrogenase (GAPDH) as inter-
nal control (housekeeping gene) was 50-TGA TGA CAT CAA
GAA GGT GGT GAA G-30 (Forward) and 50-TCC TTG
GAGGCCATGTGGGCCAT-30 (Reverse) [4]. The PCR pri-
mers were supplied by Fermentans, Germany. According to the
RQ manager program 1.2 ABI SDS software (ABI 7900HT),
the relative endogenous quantities of the PPARc gene normal-
ized against the control (GAPDH) gene fold expression changes
are calculated using the equation 2DDct [19].
2.2. Radiological assessment
Plain X-rays of both hands and feet were obtained and evalu-
ated according to the Larsen score [20].
2.3. Statistical analysis
The data were recorded on an ‘‘Investigation report form”.
These data were tabulated, coded and analyzed using the com-
puter program SPSS (Statistical package for social science)
version 16. Descriptive statistics were presented in the form
of mean and standard deviation. Mann–Whitney test was used
for the analysis of 2 non parametric quantitative data. A one
way ANOVA was used to compare more than 2 quantitative
data. The correlation between variables was performed using
Spearman’s rank correlation tests. p value < 0.05 was consid-
ered significant.
3. Results
The 30 patients had a mean age of 46.53 ± 11.8 years of whom
23 were females and 7 males (F:M= 23:7). The control groupwas of matched age and sex with a mean age of 42.3
± 12.1 years and F:M ratio of 22:8. The clinical and labora-
tory variables of Group 1A and Group 1B are shown in
Table 1. Twenty-six RA patients were on 200 mg/d hydroxy-
chloroquine, 19 patients were on oral prednisolone therapy
(7.6 ± 2.6 mg/dl), 17 were on weekly methotrexate (MTX)
injection (13.9 ± 2.01/w), 10 patients were on 20 mg lefluno-
mide and 3 were on sulfasalazine 1.8 ± 0.3 gm/d.
PPARc mRNA expression in the peripheral monocytes
showed a highly significant mean fold elevation (p< 0.001)
in RA patients (6.87 ± 0.9) than in healthy controls (Fig. 1).
The peripheral monocyte PPARc gene expression showed a
highly significant mean fold elevation in patients with remis-
sion (Group 1B) (7.6 ± 0.63) than in patients with active
RA (Group 1A) (6.13 ± 0.52) and controls (p< 0.001)
(Fig. 1).
The correlation of the monocyte PPARc gene expression
with clinical and laboratory parameters, medications, disease
activity (DAS-28), functional disability (HAQ) as well as
Larsen score is presented in Table 2.4. Discussion
The present results showed that PPARc gene expressions in
monocytes from RA patients were significantly higher
(p< 0.001) than those from the healthy subjects. This is con-
sistent with the previous observations found by Palma et al.
[21] who concluded that monocytes obtained from RA patients
present a significantly enhanced constitutive expression of
PPARc protein as compared with those from healthy donors.
Also, Jiang et al. [22] by evaluating PPARc gene expression in
bone marrow cells obtained from patients with traumatic
femoral neck fracture, OA or RA, observed that RA patients
had significantly higher PPARc mRNA expression levels than
OA patients and fractured subjects.
PPARc is a key modulator of macrophage differentiation
[16] and the fact that PPARc mRNA might be increased in
inflammatory/immune diseases is not surprising because
monocytes/macrophages participate in different inflammatory
and autoimmune disorders [23]. PPARc over-expression in
monocytes/macrophages from RA patients not only confirms
RA as a systemic inflammatory disease, but also suggests that
at the joint level, cells can be recruited from a pool of pre-
activated peripheral monocytes [21]. Increased PPARc mRNA
levels were also detected in macrophages from patients with
active SLE as compared with patients with inactive SLE or
infectious diseases and healthy subjects [24]. Koufany et al.
[25] demonstrated increased PPARc mRNA levels in a model
of adjuvant-induced arthritis.
Our findings revealed that the PPARc gene expressions in
monocytes were significantly lower in active RA patients than
in those with low activity or remission (p< 0.001) and PPARc
gene expression was inversely associated with individual mark-
ers of disease activity such as morning stiffness durations, TJC,
SJC, VAS, ESR/1st h and platelet count. This is in accordance
with the findings of Palma et al. [21] who reported a significant
inverse correlation between PPARc protein expression and
disease activity evaluated by DAS-28 score (r= 0.4,
p< 0.05). Moreover they found the highest PPARc protein
expression in monocytes from RA patients with a score
between 2 and <2.6 [21], which represents minimal disease
Figure 1 Peroxisome proliferator-activated receptor-gamma (PPARc) mRNA mean fold increase in monocytes from rheumatoid
arthritis patients (n= 30); active (n= 15) and inactive (n= 15) as well as in healthy control (n= 30).
Table 1 Clinical and laboratory characteristics of rheumatoid arthritis patients with moderate-high disease activity (Group 1A) and
with remission/low disease activity (Group 1B).
Variable
Mean ± SD
Rheumatoid arthritis (RA) patients Significance
All (n= 30) Group 1A (n= 15) Group 1B (n= 15) t p
Disease duration (y) 7.1 ± 3.9 5.9 ± 2.5 8.3 ± 4.8 1.7 >0.05
MS (min) 49.8 ± 46.5 88 ± 36.2 11.7 ± 6.5 8.02 <0.001
TJC 6.03 ± 5.1 10.4 ± 3.4 1.7 ± 1.2 9.4 <0.001
SJC 2.98 ± 2.7 4.8 ± 3 0.7 ± 0.8 5.1 <0.001
VAS (cm) 3.8 ± 2.2 5.8 ± 0.9 1.9 ± 0.7 12.7 <0.001
DAS-28 3.9 ± 1.5 5.2 ± 0.9 2.6 ± 0.5 10.1 <0.001
Larsen score 20.3 ± 14.9 19.9 ± 3.9 20.7 ± 21.1 0.2 >0.05
HAQ 1.7 ± 0.7 2.27 ± 0.3 1.05 ± 0.3 12.7 <0.001
ESR (mm/1st h) 32 ± 24.9 48 ± 26.2 16.6 ± 6.9 29.6 <0.001
CRP (mg/l) 25.5 ± 22.3 10.9 ± 0.7 11.3 ± 1.03 20.4 <0.001
Hb (g/dl) 11.1 ± 0.8 7.8 ± 1.6 6.7 ± 1.6 0.4 >0.05
WBC (103/mm3) 7.3 ± 1.7 7.8 ± 1.6 6.7 ± 1.6 0.4 >0.05
Platelets (103/mm3) 325.7 ± 91.1 338.9 ± 112.3 312.5 ± 64.6 1.9 >0.05
Group 1A: moderate-high disease activity, Group 1B: remission/low disease activity, MS: morning stiffness, TJC: tender joint count, SJC:
swollen joints count, VAS: visual analog scale, DAS-28: 28-joint disease activity score, HAQ: health assessment questionnaire, ESR: erythrocyte
sedimentation rate, CRP: C-reactive protein, Hb: hemoglobin, WBC: white blood cells. Bold values are significant between Groups 1A and 1B
at p< 0.001.
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[26]. The inverse relationships between the amount of the
PPARc expression and the degree of disease activity can be
explained by the fact that classically activated inflammatory
macrophages (M1) that secrete higher levels of pro-
inflammatory genes and probably contribute to inflammation
and (M2) macrophages, the less inflammatory, alternatively
activated macrophages can switch from one phenotype to the
other [27]. Therefore the local environment created by theactivation of PPARc might induce a switch from M1- toward
M2-activated macrophages, thus contributing to the
anti-inflammatory effect [28]. Moreover, PPARc agonists exert
beneficial effects on inflammatory conditions, including
autoimmune diseases, by shifting the pattern of
immune response through the modulation of the T-helper 1
(Th1)/T-helper2 (Th2) balance [29]. Guyton et al. [30] found
PPARc in the macrophages where its binding to agonists
suppresses pro inflammatory processes. High concentrations
Table 2 Correlations between monocytes peroxisome prolif-
erator-activated receptor-gamma (PPARc) expression and
clinical and laboratory parameters, medications, disease activ-
ity and disability as well as radiological score in rheumatoid
arthritis patients (n= 30).
Variable PPARc expression
r p
Clinical
Disease duration 0.45 <0.05
MS (min) 0.7 <0.001
TJCs 0.63 <0.001
SJCs 0.54 <0.05
VAS for pain (cm) 0.76 <0.001
Laboratory
ESR (mm/1st h) 0.26 <0.05
CRP (mg/l) 0.02 >0.05
Hemoglobin (g/dl) 0.56 >0.05
Platelets (103/mm3) 0.02 <0.05
WBC (103/mm3) 0.12 >0.05
RF (IU/ml) 0.07 >0.05
ACPA (IU/ml) 0.16 >0.05
Radiological
Larsen scores 0.10 >0.05
Disease activity
DAS-28 0.72 <0.001
Functional disability
HAQ 0.59 <0.001
Medications
Steroid dose 0.1 >0.05
Duration 0.45 >0.05
MTX duration 0.65 <0.05
MS: morning stiffness, TJCs: tender joint counts, SJCs: swollen
joint counts, VAS: visual analog scale, DAS: disease activity score,
HAQ: health assessment questionnaire .ESR: erythrocyte sedi-
mentation rate, CRP: C-reactive protein, WBC: white blood cells,
RF: rheumatoid factor, ACPA: anti-citrullinated peptide antibody,
MTX: methotrexate. Bold values are significant at p< 0.001 and
p< 0.05.
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activities by inhibiting the secretion of interleukin-1 (IL-1),
interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-a)
by stimulated monocytes [31]. Kawahito et al. [32] reported
that PPARc mRNA was expressed in the synovial cells and
showed that intraperitoneal injection of PPARc agonists alle-
viated adjuvant induced arthritis.
Most of our RA patients were treated with oral prednisone,
hydroxychloroquine and methotrexate. Our study revealed no
significant correlation between PPARc expression in
monocytes and steroid dose or duration, although there was
a significant correlation with the duration of MTX therapy.
Palma et al. [21], evaluated the effect of MTX and methylpred-
nisolone on the expression of PPARc in monocytes and
concluded that both enhance expression and act as PPARc
agonists that contribute to overall therapeutic activity, and
their clinical efficacy in RA. This was also previously demon-
strated in a study showing that indomethacin and other
selected non-steroidal anti-inflammatory drugs (NSAIDs),
telmisartan and some statins act as PPARc agonists whichcontribute to their overall clinical efficacy [33]. In this context,
it is worth noting that RA patients with a DAS-28 score <3.2,
which reasonably identifies those patients in whom MTX and
corticosteroids are effective in controlling disease severity,
express significantly higher PPARcmRNA levels than patients
with a score >3.2, which could indicate inadequately respond-
ing patients.
The findings of Shahin et al. [34] suggest that PPARc ago-
nist (pioglitazone) could be a potential therapeutic agent for
RA. To the best of our knowledge the study by Shahin et al.
[34] was the first clinical study evaluating the effects of a
PPAR-c agonist (pioglitazone) combined with MTX as ther-
apy for RA. In their study, the patients treated with pioglita-
zone exhibited significant clinical and laboratory
improvement. Also, there were significant reductions in the
ESR, CRP and DAS28 compared to the placebo treated group
of patients. Of note, there was no difference in the blood glu-
cose level between the two groups at the end of the study, indi-
cating that the improvement in disease activity indices and
markers was not due to the anti diabetic effect of pioglitazone.
These results could be explained by the suggested anti-
inflammatory effects of PPARc ligands. Studies have indicated
that many of the cells involved with RA, namely mononuclear
leukocytes [35] and chondrocytes [36] express PPARc recep-
tors. In fact; induction of protective receptors could be a
relatively common downstream feature of disease modifying
anti-rheumatic drugs (DMARDs).
In conclusion, PPARc protein expression in RA patients is
inversely related to RA disease activity. Our findings support
the role of PPARc in the pathophysiology of RA and suggest
that over-expression of PPARc protein may have anti-
rheumatic effects. Further studies on a larger group of RA
patients with follow up to explore the anti inflammatory effect
of PPARc and follow the efficiency of therapy are needed.
Conduction of more studies on the PPARc agonist to evaluate
its effect on RA disease progression and severity is
recommended.Conflict of interest
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